Real world analysis of high-cut-off (HCO) hemodialysis with bortezomib-based backbone therapy in patients with multiple myeloma and acute kidney injury
Sign Up to like & getrecommendations! Published in 2020 at "Journal of Nephrology"
DOI: 10.1007/s40620-020-00939-2
Abstract: In patients with multiple myeloma (MM) free light chain-induced cast nephropathy is a serious complication associated with poor survival. High-cut-off (HCO) hemodialysis can reduce the amount of serum free light chains (sFLC), but data on… read more here.
Keywords: hemodialysis; nephrology; hemodialysis bortezomib; bortezomib based ... See more keywords
Efficacy and toxicity of carfilzomib- or bortezomib-based regimens for treatment of transplant-ineligible patients with newly diagnosed multiple myeloma: A meta-analysis
Sign Up to like & getrecommendations! Published in 2022 at "Medicine"
DOI: 10.1097/md.0000000000030715
Abstract: Background: Multiple myeloma is a clonal disorder of malignant plasma cells that comprises approximately 10% of hematologic malignancies. The aim of this study was to investigate the efficacy and toxicity of carfilzomib- or bortezomib-based regimens… read more here.
Keywords: based regimens; ineligible patients; transplant ineligible; bortezomib based ... See more keywords
The impact of bortezomib-based induction in newly diagnosed multiple myeloma with chromosome 1q21 gain
Sign Up to like & getrecommendations! Published in 2022 at "Therapeutic Advances in Hematology"
DOI: 10.1177/20406207221082043
Abstract: Introduction: Bortezomib has been reported to favourably impact the outcomes of t(4;14) and del(17p) in multiple myeloma (MM), but its impact on gain 1q (+1q) is unknown. Methods: To address this, 250 patients treated with… read more here.
Keywords: multiple myeloma; bortezomib based; based induction;
Autologous Stem Cell Transplant in the Era of Bortezomib-Based Induction for AL Amyloidosis – A Single Institution 11 Year Experience
Sign Up to like & getrecommendations! Published in 2018 at "IEEE Transactions on Biomedical Engineering"
DOI: 10.32392/biomed.7
Abstract: 1. Department of Internal Medicine 2. Center for Hematologic Malignancies, Knight Cancer Institute 3. Department of Neurology 4. Division of Nephrology & Hypertension 5. Knight Cardiovascular Institute, Oregon Health & Science University, Portland, Oregon Citation:… read more here.
Keywords: transplant era; stem cell; bortezomib based; era bortezomib ... See more keywords
The Relationship between Serum miRNAs and Early Mortality in Multiple Myeloma Patients Treated with Bortezomib-Based Regimens
Sign Up to like & getrecommendations! Published in 2023 at "International Journal of Molecular Sciences"
DOI: 10.3390/ijms24032938
Abstract: Multiple myeloma (MM) is a hematological malignancy characterized by the clonal proliferation of plasma cells in the bone marrow (BM) microenvironment. Despite the progress made in treatment, some MM patients still die within the first… read more here.
Keywords: based regimens; treated bortezomib; mortality; early mortality ... See more keywords
Evaluation of serum glucose-regulated protein 78 (GRP78) as a biomarker of treatment response to bortezomib-based induction regimen in multiple myeloma: A cross-sectional pilot study.
Sign Up to like & getrecommendations! Published in 2022 at "Neoplasma"
DOI: 10.4149/neo_2022_220526n564
Abstract: GRP78 overexpression in myeloma cells has been associated with bortezomib resistance in multiple myeloma (MM). However, serum GRP78 as a maker of bortezomib-based treatment response remains unexplored. The objective of the study was to evaluate… read more here.
Keywords: based induction; grp78; serum grp78; bortezomib based ... See more keywords